Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 12: 475-481, 1966;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Amador, E.
Right arrow Articles by Massod, M. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Amador, E.
Right arrow Articles by Massod, M. F.

Clinical Chemistry, Vol 12, 475-481, Copyright © 1966 by the American Association for Clinical Chemistry

Serum Glutamic-Oxaloacetic Transaminase Activity: Diagnostic Accuracy of the Revised Spectrophotometric and the Dinitrophenylhydrazine Methods

Elias Amador 1, Robert J. Franey 1, and Mary F. Massod 1

1 Pathology Research Center, Peter sent Brigham Hospital and Harvard Medical School, Boston 02115, and the Department of Pathology, Brockton Hospital, Brockton, Mass.

The diagnostic accuracy of two methods for measuring serum glutamic-oxaloacetic transaminase activity was examined in 50 cases of acute myocardial infarction proven by autopsy and in 12 nonfatal cases documented by rigid clinical criteria. All activities measured with the revised spectrophotometric method were elevated during the second day after infarction, and all patients had an elevated activity. The spectrophotometric method therefore had a diagnostic accuracy of 100%.

Activities measured with the dinitrophenylhydrazine method of Reitman and Frankel were elevated in only 68% of cases during the second day after infarction, and the activity was elevated in only 76% of all the patients during the first 4 days. Dinitro-phenylhydrazine-measured activities were therefore 20-30% inaccurate. The diagnostic inaccuracy of the dinitrophenylhydrazine method could result in 300,000 false-negative diagnoses of acute myocardial infarction each year in the United States alone.

Submitted on December 23, 1965
Accepted on March 23, 1966






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1966 by the American Association for Clinical Chemistry.